PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT00303953 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

NIH

Sponsor class

Conditions

Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma

Interventions

DRUG: belinostat

Sponsor

National Cancer Institute (NCI)